PER-026-22招募中3 期
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Merck Sharp & Dohme LLC., (una subsidiaria de Merck & Co. Inc.)0 个研究点目标入组 0 人开始时间: 2023年9月14日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Participants are currently enrolled in MSD-sponsored pembrolizumab trials and are receiving trial treatment or in a follow-up phase at the time KN-587 is open. Participants must be from MSD-sponsored pembrolizumab parent trials established by the Sponsor as KN-587 transition-ready.
- •NOTE: Parent trial participants in survival follow-up who are not eligible to receive treatment in KN-587 may complete transitioning to KN-587 after close-out of the parent MSD trial.
- •The participant (or legally acceptable representative if applicable) provides informed consent for the trial and agrees to follow study procedures.
排除标准
- •There are no exclusion criteria to participate in KN-587.
研究者
相似试验
招募中
1 期
Extension Study for Participants in Studies That Include PembrolizumabAdvanced tumorsMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104CTIS2022-501254-10-00Merck Sharp & Dohme LLC3,478
进行中（未招募）
1 期
A clinical study to evaluate immune responses to rabies vaccine in adults who received different primary rabies vaccination regimens.MedDRA version: 20.0Level: PTClassification code 10037742Term: RabiesSystem Organ Class: 10021881 - Infections and infestationsRabiesEUCTR2015-000382-31-ATGlaxoSmithKline Biologicals S.A.578
已完成
3 期
A Study of Guselkumab in Participants with Moderately to Severely Active Crohn's DiseaseCrohn's DiseaseJPRN-jRCT2080225202Janssen Pharmaceutical K.K.25
尚未招募
3 期
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisGeneralized Pustular PsoriasisErythrodermic PsoriasisJPRN-jRCT2071230104akano Masayoshi16
招募中
1 期
Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic ArthritisJuvenile Psoriatic ArthritisMedDRA version: 20.0Level: PTClassification code 10076674Term: Juvenile psoriatic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2020-005503-40-NLJanssen-Cilag International NV80